Observational analysis assessed treatment response in a man with metastatic melanoma, indicating 68Ga-FAPI may be superior to 18F-FDG PET/CT.
A 59-year-old man with metastatic melanoma and brain metastases underwent brain radiotherapy. Following treatment, he developed neurological symptoms, prompting further evaluation. To assess the treatment response and possibility of Lutetium-177-FAPI therapy, both 18 F-FDG PET/CT and 68 Ga-FAPI-46 PET/CT scans were performed. The 18 F-FDG PET/CT was inconclusive due to posttreatment changes, making it challenging to distinguish between tumor progression and therapy-related alterations. In contrast, the 68 Ga-FAPI-46 PET/CT revealed multiple areas of increased FAPI uptake, indicative of viable residual lesions and consistent with MRI findings.
No takes yet. Share an insight, caveat, or question.
Divband et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: